USFDA completes cGMP inspection of Biocon’s Bangalore facility

24 Sep 2018 Evaluate

US Food and Drug Administration (USFDA) has conducted a periodic cGMP inspection of Biocon’s Drug Substance manufacturing site at Bangalore Campus from September 17 - 21, 2018. After the inspection there was no observations found. The successful audit of this site reflects the company’s strong commitment to cGMP compliance.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

377.55 -1.50 (-0.40%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×